|Title||CHA Biotech Announces Completion of Phase I/IIa Trial in Stroke|
|- CHA Biotech submits a ‘Study Closure Report’ of Stroke Phase I/IIa study to MFDS (Ministry of Food and Drug Safety in Korea) on April 24th.
- The study was conducted at Bundang CHA Medical Center and a total of 18 patients were followed up for 6 months.
- CHA Biotech expects to report top-line efficacy results in the 2nd half of 2017 and will move forward to initiate Phase IIb clinical trial.
- If outstanding clinical trial results are achieved, CHA Biotech also has a plan to conduct clinical trial abroad.
- CHA Biotech’s umbilical cord adherent stem cell therapy for stroke is one of its core cell therapy pipelines and expected to be the 1st commercialized in-house pipeline.